

Cover Story
Free
Duke University would have avoided embarrassment, a misconduct investigation and a lawsuit, had its top administrators paid closer attention to a thoughtful report by a medical student who saw problems in the lab of the disgraced scientist Anil Potti.
In Brief


Drugs & Targets


Trending Stories
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Why both somatic and germline genomic profiling are essential for precision oncology










